Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Average PT from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $27.00.

Separately, HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th.

Insider Activity at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 8,256 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $77,358.72. Following the transaction, the director now directly owns 772,277 shares of the company's stock, valued at approximately $7,236,235.49. This represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean Bohen sold 52,328 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the transaction, the chief executive officer now owns 298,836 shares of the company's stock, valued at approximately $2,800,093.32. The trade was a 14.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 773,797 shares of company stock valued at $5,414,609 in the last three months. 19.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of large investors have recently bought and sold shares of OLMA. Point72 Asset Management L.P. purchased a new position in shares of Olema Pharmaceuticals during the 2nd quarter valued at about $34,753,000. Great Point Partners LLC acquired a new stake in Olema Pharmaceuticals during the second quarter valued at $8,622,000. Candriam S.C.A. increased its holdings in Olema Pharmaceuticals by 199.9% in the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company's stock valued at $11,454,000 after buying an additional 705,655 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of Olema Pharmaceuticals in the second quarter worth about $2,976,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Olema Pharmaceuticals by 168.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company's stock worth $3,949,000 after acquiring an additional 207,565 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock traded up $0.31 during mid-day trading on Friday, hitting $6.10. 1,281,874 shares of the stock traded hands, compared to its average volume of 770,595. Olema Pharmaceuticals has a 52-week low of $5.56 and a 52-week high of $16.77. The stock has a market cap of $349.52 million, a P/E ratio of -2.79 and a beta of 1.92. The stock's fifty day moving average is $10.17 and its two-hundred day moving average is $11.71.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.